FDA Signals Broader Cosmetics Oversight Under MoCRA Law

The Food and Drug Administration is preparing to enforce cosmetics rules more aggressively as it moves further into implementing the Modernization of Cosmetics Regulation Act, according to a client alert from the law firm Kelley Drye & Warren LLP titled "FDA Signals Increased Cosmetics Oversight through MoCRA Implementation and Other Regulatory Efforts."

The alert, aimed at companies that manufacture, package or distribute beauty and personal-care products sold in the United States, describes an agency turning its attention toward enforcing obligations that MoCRA created for the industry, including facility registration, product listing, safety substantiation and reporting of serious adverse events. Kelley Drye's alert frames the current period as one in which the FDA is signaling — through guidance, warning letters and other regulatory activity — that those obligations will be enforced rather than left dormant.

What Is MoCRA and Why Does It Cover Cosmetics Now?

MoCRA gave the FDA authority over cosmetics that the agency had not previously held, shifting the industry from a largely self-regulated model toward one built around federal registration, listing and safety-substantiation requirements. Kelley Drye's alert situates its warning within that broader shift, describing FDA activity around MoCRA implementation as part of a pattern the firm says cosmetics companies should not ignore.

What Does the Kelley Drye Alert Say Companies Should Expect?

"FDA Signals Increased Cosmetics Oversight through MoCRA Implementation and Other Regulatory Efforts" — Kelley Drye & Warren LLP client alert

The firm's alert lays out the specific regulatory actions it says point toward heightened FDA attention. Companies operating in the space are advised to review the full alert directly rather than rely on secondhand summaries, given the compliance stakes involved.

How Could Heightened Oversight Affect Beauty and Skincare Brands?

Any expansion of enforcement under MoCRA would reach companies across the size spectrum, from large cosmetics manufacturers to smaller independent skincare brands, including those selling retinol- and retinal-based treatments, an ingredient category HTT News has covered separately. Brands that have not completed facility registration or product listing, or that lack documentation supporting safety claims, would face the most direct exposure if the FDA follows through on the posture described in the alert.

What Should Consumers and Companies Watch For Next?

• Additional FDA guidance documents clarifying MoCRA compliance expectations
• Warning letters or enforcement actions reported by trade press or the FDA itself
• Statements from the FDA outlining priorities for cosmetics safety substantiation
• Updates from law firms and trade groups tracking the agency's implementation timeline

Consumers researching ingredient safety in the meantime can find general guidance in HTT News' related coverage on building a skin care routine and on retinol versus retinal, though neither piece addresses the FDA's regulatory posture directly.

The Kelley Drye & Warren alert remains the primary public source detailing the specific regulatory signals described in this report; readers seeking the underlying legal analysis should consult the firm's full client alert.